Micropoint Bioscience, Inc.
Micropoint Bioscience, Inc. is a global provider of rapid, accurate, point-of-care testing (POCT) systems and solutions. Reducing the time required to diagnose a cardiac event can be a key factor in saving the lives of patients with acute heart conditions. Micropoint`s point-of-care and nearside products enable medical and caregiving teams to test for a range of cardiac disease markers, efficiently manage patient hospital stay, and provide support for an improved quality of life back at home. The company`s innovative mLabs and qLabs platforms, based on groundbreaking MEMS and microfluidics technology, offer both bedside and wireless handheld testing for accurate results within minutes. Founded in 2006, Micropoint Bioscience, Inc. is headquartered in Santa Clara, California. The company’s Chinese operations are located in Shenzhen. Micropoint’s manufacturing facilities in the U.S. and China are both GMP-and ISO13485 certified.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
Our Vision
Micropoint is committed to providing medical professionals and patients with rapid point-of-care diagnostics and self-test products and systems that can enhance quality of care while increasing patient quality of life.
The combination of several trends, including an aging population, increasingly informed patients, and constantly improving technology means that the medical community will need to provide data-driven therapy, more personalized medicine, and earlier detection of cardiovascular disease, blood thinning conditions and infection.
Micropoint seeks to be at the forefront of these trends by developing innovative products and solutions that can quickly and reliably provide data that support medical decision-making, from hospital or home.
Our Market
Micropoint's rapid point-of-care and home test products span a range of clinical applications for medical teams seeking to expedite diagnosis and evaluation where accuracy and early intervention is critical. These life-threatening diseases burden society with mounting healthcare costs in the hundreds of billions per year. Micropoint's point-of-care diagnostic tests help lower costs by quickly detecting conditions and events early -- in hospital, or at home through self-testing -- so that medical teams can determine the most effective preventive therapy and get patients back to their lifestyles.
We have strong expertise in cardiovascular disease diagnostics and assessment, including heart failure, myocardial infarctions, and embolisms. We provide a range of tests for anticoagulants used in stroke, heart attack and venous thromboembolisms, including deep vein thrombosis (DVT) and pulmonary embolisms (PE). Our tests for sepsis and severe systemic bacterials infections enable medical teams to differentiate between infection types. The company is constantly researching new application areas for pressing medical needs. Micropoint is currently readying lipids and glucose tests for the market.